• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文OA文献 >The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
【2h】

The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

机译：硅二蛋白酶单疗法的持续性以及戒断以前未经治疗的日本患者患者患有良性前列腺增生症状的患者

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives. The persistence of silodosin and the reasons for withdrawal from treatment of previously untreated Japanese patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) were evaluated in real-life clinical practice. Methods. A total of 81 previously untreated Japanese patients diagnosed with LUTS/BPH were treated with silodosin monotherapy and prospectively followed for 4 years. The persistence rate was estimated using the Kaplan-Meier method. If silodosin had to be terminated or a patient did not come to the hospital, the reason was determined. Results. The 6-month, 1-year, 2-year, 3-year, and 4-year persistence rates were 63.0%, 56.8%, 50.6%, 44.4%, and 35.8%, respectively. The most frequent reason (22.2%) for withdrawal was symptom resolution. After silodosin treatment, the international prostate symptom score and the quality of life index were significantly improved and maintained for 4 years. Conclusions. 35.8% of previously untreated Japanese patients continued silodosin for 4 years. Many patients terminated silodosin for various reasons, the most frequent of which was symptom resolution. The effects of silodosin were maintained when the patients continued treatment. Trial Registration. This study was approved by the institutional review board of Hokkaido Prefectural Esashi Hospital (number 2007-2) and was registered in a public trial registry (UMIN000026910).
机译：目标。良性前列腺增生症的西洛多辛持续存在的原因及治疗，从以前未经治疗的日本患者有下尿路症状的撤离提示（LUTS / BPH）在现实生活中的临床实践进行了评价。方法。确诊为LUTS / BPH共81名以前未经治疗的日本患者用单药西洛多辛处理和前瞻性随访了4年。持久性率是使用Kaplan-Meier方法估算。如果西洛多辛不得不终止或病人没来医院，原因是确定的。结果。 6个月，1年，2年，3年，4年的持久性率分别为63.0％，56.8％，50.6％，44.4％，和35.8％之间。其提取的最常见的原因（22.2％）明显症状缓解。西洛多辛治疗后，国际前列腺症状评分和生活质量指数均显著改善并维持了4年。结论。以前未经治疗的日本患者的35.8％，继续西洛多辛4年。许多患者终止西洛多辛由于种种原因，其中最常见的是症状缓解。西洛多辛的影响进行维护时，患者继续治疗。试验注册。本研究通过北海道枝幸医院（2007-2号）的机构审查委员会，并在公共试验注册（UMIN000026910）的注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号